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ABSTRACT
We evaluated the outcomes of allogeneic hematopoietic cell transplantation (HCT) in 43 patients with chronic
myelomonocytic leukemia. Patients were classified according to the French-American-British and World
Health Organization classifications, as well as the International Prognostic Scoring System and the M.D.
Anderson prognostic score. Comorbidity scores were assessed by using an HCT-specific comorbidity index.
Patients were aged 1 to 66 years (median, 48 years). Twenty-one patients received transplants from related
donors (18 HLA-identical siblings and 3 HLA-nonidentical family members), and 22 received transplants from
unrelated donors (18 HLA matched and 4 HLA nonidentical). Several busulfan or total body irradiation–based
conditioning regimens were used. Sustained engraftment was achieved in 41 patients. Eighteen are alive at 1.9
to 14.1 years, for an estimated relapse-free survival of 41% at 4 years. Ten patients have relapsed, thus leading
to a cumulative incidence of 23% at 4 years. Risk category by International Prognostic Scoring System, World
Health Organization, M.D. Anderson prognostic score, or proliferative/dysplastic status had no statistically
significant association with outcomes. However, patients with higher comorbidity scores had worse overall
survival than patients with lower scores (P  .01). There was a trend for a higher relapse incidence among
patients at higher risk by the M.D. Anderson prognostic score. The data suggest that patients with few or no
comorbidities and those who undergo transplantation earlier in the disease course have the highest probability
of successful outcome after allogeneic HCT.
© 2005 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Chronic myelomonocytic leukemia (CMML) is a
yeloid disorder, often with features of myelodyspla-
ia and, more prominently, myeloproliferation, classi-
ed by the World Health Organization (WHO) as a
yelodysplastic/myeloproliferative disorder [1]. To
ate, no speciﬁc cytogenetic or molecular distinction
s possible between patients with more dysplastic and
hose with more proliferative features. According to
he WHO, the disorder is subdivided into CMML-1
nd CMML-2 according to the proportion of myelo-
lasts in peripheral blood and marrow and the pres-
nce or absence of Auer rods [1]. Investigators at M.D.
nderson have proposed a new prognostic classiﬁca-
ion that is based on analysis of disease characteristics s
B&MTnd survival in 213 patients with CMML [2]. Al-
hough the median survival was 12 months, they iden-
iﬁed 4 subgroups of patients with median survivals of
4, 15, 8, and 5 months on the basis of hemoglobin
evels, the presence of circulating immature myeloid
ells, the absolute lymphocyte count, and the marrow
yeloblast proportion. Despite the designation as a
hronic leukemia, CMML is a progressive disease that
ften leads to death within months. Various chemo-
herapy regimens have been used, including hy-
roxyurea, etoposide, low-dose cytosine arabinoside,
r more intensive combinations of cytotoxic agents
uch as anthracycline and cytosine arabinoside. How-
ver, responses to such therapies have generally been
hort. More recently developed agents, such as farne-
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7yl transferase inhibitors, have met with limited suc-
ess [3,4]. The tyrosine kinase inhibitor imatinib me-
ylate (STI571) may induce remissions, but typically
nly in patients with mutations or gene rearrange-
ents (for example, involving platelet-derived growth
actor receptor ) that generate appropriate targets
5]. The only currently available therapy that offers
he potential for cure is hematopoietic cell transplan-
ation (HCT) [6-8]. We previously reported results
ith allogeneic transplantation in 21 patients with
MML [6]. Here, we update our data and summarize
esults in 43 patients treated at the Fred Hutchinson
ancer Research Center (FHCRC) in Seattle, WA.
ATIENTS AND METHODS
atients
Between June 1990 and January 2004, 43 patients
ith CMML received transplants from allogeneic do-
ors at the FHCRC. Patient and disease characteris-
ics are summarized in Table 1. The diagnosis of
MML was initially based on the French-American-
ritish classiﬁcation. For the purpose of this analysis,
he disease was also classiﬁed according to WHO
riteria [1]. In addition, we categorized patients for
hom all required parameters were available accord-
ng to the 4 risk groups recently proposed by Onida et
l. [2] (M.D. Anderson Prognostic Score [MDAPS]).
ll classiﬁcations in this analysis were based on ﬁnd-
ngs at the time of transplantation rather than at di-
gnosis.
Patients were 1 to 66 years (median, 48 years) of
ge at the time of transplantation. Twenty-ﬁve pa-
ients were male, and 18 were female. The interval
rom diagnosis to transplantation was 2 to 156 months
median, 8 months). At the time of transplantation, 16
atients were classiﬁed as having proliferative CMML
white blood cell count [WBC] of 13  109/L), and
7 had nonproliferative CMML (WBC of 13 
09/L) [9]. Lymphocyte counts ranged from 0.04 to
1.86  109/L, with a median of 1.8  109/L. Five
atients had what was considered secondary CMML
fter therapy for aplastic anemia (n  2), Hodgkin
isease (n  1), POEMS syndrome (polyneuropathy,
rganomegaly, endocrinopathy, M protein, and skin
hanges; n  1), and chronic lymphocytic leukemia
n  1). Three patients had undergone splenectomy.
welve patients had received either no treatment or
ransfusion only before transplantation. Fourteen pa-
ients had received hydroxyurea, 6 had received ste-
oids or erythropoietin (or both), 2 had received ima-
inib, and 9 had received various kinds of
hemotherapy other than hydroxyurea.
There were 26 patients with nonproliferative
MML who could be scored according to the In-ernational Prognostic Scoring System (IPSS). h
14mong these, 4 were low risk, 11 were intermediate
, 8 were intermediate 2, and were 3 high risk [10].
y IPSS criteria, 23 patients had good-risk cytoge-
etics (normal karyotype), 9 had poor-risk cytoge-
etics (monosomy 7 in 5 and complex abnormalities
n 4 patients), and 11 had intermediate-risk cytoge-
etics (3 with trisomy 8, single miscellaneous in 5,
nd double miscellaneous in 2). Overall, 32 patients
ad CMML-1 and 11 had CMML-2 by WHO cri-
eria. By the M.D. Anderson criteria, considering
emoglobin 12 g/dL, immature myeloid cells in
eripheral blood, marrow blasts 10%, and abso-
ute lymphocyte counts of 2.5  109/L, 18 pa-
ients were in the low-risk category, 9 were inter-
ediate 1, 12 were intermediate 2, and 4 were in the
able 1. Patient Characteristics at Transplantation
Variable Data
opulation studied 43
ge (y) 48 (1-66)
ex (male/female) 25/18
isease duration (mo) 8 (2-156)
iagnosis
Proliferative 16
Nonproliferative 27
WHO—CMML-1/2 32/11
IPSS risk (26 scored)
Low 4
Int-1 11
Int-2 8
High 3
MDAPS
Low 18
Int-1 9
Int-2 12
High 4
MV serology (/) 24/19
ematologic parameters
Lymphocytes ( 109/L) 1.8 (0.04-11.86)
WBC/ANC ( 109/L) 8.8 (0.34-127)/2.913 (0.06-43.46)
Platelets ( 109/L) 59 (3-594)
Hemoglobin (g/dL) 10.2 (4.8-16.9)
ytogenetic findings
Normal 23
Monosomy 7 ( others) 5
Other abnormalities 15
retransplantation therapy
None 9
Transfusion only 3
Imatinib 2
Hydroxyurea 14
Combination
chemotherapy 9
Erythropoietin 2
Prednisolone 4
Splenectomy 3
HO indicates World Health Organization; IPSS, International
Prognostic Scoring System; MDAPS, M.D. Anderson Prognos-
tic Score; CMV, cytomegalovirus; Int, intermediate; ANC, ab-
solute neutrophil count.
ata are n or median (range).igh-risk category.
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Allogeneic Transplants for CMML
Bomorbidities
Information concerning comorbidities was ob-
ained through medical chart review. Comorbidities
ere scored by using a recently developed HCT-
peciﬁc comorbidity index (HCT-SCI). This index
as developed by modifying the Charlson comorbid-
ty index [11], and it has shown good prediction for
he risks of nonrelapse mortality and overall survival
12]. Speciﬁc comorbidities, deﬁnitions, and assigned
eights were assessed as previously described [13].
CT-SCI could be applied for 42 patients. Thirteen
atients had a score of 0; 5, a score of 1; 11, a score of
; 8, a score of 3; 2, a score of 4; 1, a score of 5, and
, a score of 6 [12].
onors and Sources of Hematopoietic Stem Cells
Transplant characteristics are summarized in Ta-
le 2. Patients and donors were typed for HLA-A, -B,
C, -DRB1, and -DQB1. Eighteen patients received
arrow from HLA-identical siblings, 3 from HLA-
onidentical family members (parent, sibling, or child
iffering for HLA-A; HLA-A, -B, and -DR; and
LA-A and -DR, respectively), 17 from HLA-
atched unrelated donors, and 5 from HLA-noniden-
ical unrelated donors. Among these, 3 differed from
he patients for HLA-A, and 2 differed from the pa-
ients for HLA-DR. All HLA-nonidentical transplants
ere from donors mismatched at the antigen level.
wenty-three patients received bone marrow, and 20
atients received granulocyte colony-stimulating fac-
or–mobilized peripheral blood as the source of stem
ells.
onditioning Regimen
The conditioning regimens used were determined
y sequential protocols designed for patients with my-
lodysplastic syndrome (MDS) that were active at the
ime of transplantation (Table 2). Nine patients were
onditioned with busulfan (BU) 7 mg/kg orally, cy-
lophosphamide (CY) 50 mg/kg intravenously, and
otal body irradiation (TBI) 6  200 cGy over 3 days
or a total of 12 Gy. Eight patients received BU 7
g/kg orally and fractionated TBI 6  200 cGy over
days for a total of 12 Gy. Four patients received
udarabine 120 mg/m2 intravenously over 3 days and
U 16 mg/kg orally over 4 days (targeted to plasma
evels of 800-900 ng/mL). Three patients received
argeted BU 16 mg/kg, CY 120 mg/kg, and antithy-
ocyte globulin (Thymoglobulin; Genzyme, Cam-
ridge, MA) 4.5 mg/kg over 3 days. Three patients
eceived CY 120 mg/kg and TBI 14.4/13.2 Gy, and 12
atients received BU 16 mg/kg and CY 120 mg/kg. Of
he remaining 4 patients, 1 received BU 7 mg/kg, TBI
2 Gy, and amifostine 340 mg/m2; 1 received CY 120
g/kg, antithymocyte globulin 90 mg/kg, and TBI
3.2 Gy; 1 received ﬂudarabine 90 mg/m2 and TBI 2.0 d
B&MTy; and 1 received TBI 2.0 Gy plus iodine 131–anti-
D45 antibody (approximately 18 Gy was delivered to
iver plus bone marrow) [14-20].
raft-versus-Host Disease Prophylaxis
Graft-versus-host disease (GVHD) prophylaxis
onsisted of cyclosporine and methotrexate in 38 pa-
ients. Two patients were treated with prednisone in
ddition to the cyclosporine and methotrexate, 2 were
reated with cyclosporine and prednisone, and 1 was
reated with methotrexate and tacrolimus [21-23].
valuation
Time of engraftment was deﬁned as the ﬁrst of 3
onsecutive days on which the absolute neutrophil
ount reached 0.5  109/L [24]. GVHD was deter-
ined by previously established criteria [21,25]. Sur-
ival time was the time from transplantation until
eath or the date of last contact. Relapse-free survival
as the time from transplantation until relapse or
able 2. Donor and Transplant Characteristics
Variable Data
onor age, y, median (range) 38 (3-69
ex (male/female) 26/17
onor/patient CMV status
/ 13
/ 6
/ 16
/ 8
onor-patient relationship
HLA-identical sibling 18
HLA-nonidentical related donor 3
HLA-identical unrelated donor 17
HLA-nonidentical unrelated donor 5
reparative regimen
BU (7 mg/kg)/CY (50 mg/kg)/TBI (12 Gy) 9
BU (7 mg/kg)/TBI (12 Gy) 8
BU (7 mg/kg)/TBI (12 Gy)/amifostine (340 mg/m2) 1
BU (14 mg/kg)/CY (120 mg/kg) 12
BU (16 mg/kg)/CY (120 mg/kg)/THY (4.5 mg/kg) 3
CY (120 mg/kg)/TBI (14.4/13.2 Gy) 3
CY (120 mg/kg)/ATG (90 mg/kg)/TBI (13.2 Gy) 1
FLU (90 mg/m2)/TBI (2 Gy) 1
FLU (120 mg/m2)/BU (16 mg/kg) 4
TBI (2.0 Gy)/iodine 131–anti-CD45 antibody 1
VHD prophylaxis
CSP/MTX 38
CSP/MTX/prednisone 2
CSP/prednisone 2
MTX/tacrolimus 1
ells transplanted, median (range)
Bone marrow cell dose: 2.693 (0.709-7.823)  108/kg 23
Peripheral blood stem cells, CD34 cell dose: 8.755
(4.38-33.75)  106/kg 20
MV indicates cytomegalovirus; BU, busulfan; CY, cyclophos-
phamide; TBI, total body irradiation; FLU, ﬂudarabine;
ATG, antithymocyte globulin (Thymoglobulin); CSP, cyclo-
sporine; MTX, methotrexate.
ata are numbers of patients unless otherwise noted.eath from non–relapse-related causes. Relapse was
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7eﬁned as the detection of reappearance of morpho-
ogic criteria of CMML or detection of previously
resent cytogenetic abnormalities.
tatistical Analysis
Overall and relapse-free survivals were summa-
ized by using the Kaplan-Meier method [26], and
elapse probabilities were obtained from cumulative
ncidence estimates. Death without relapse (nonre-
apse mortality) was considered a competing risk for
elapse. Cox regression was used to assess the associ-
tion of various factors with each of these outcomes.
actors analyzed included IPSS, WHO, MDAPS, and
CT-SCI scoring systems; age; duration of disease;
resence of proliferative disease; and the use of high-
ose TBI as part of the conditioning. The association
f GVHD with outcome was assessed by modeling
VHD as a time-dependent covariate. All 2-sided P
alues associated with regression models were ob-
ained by using the Wald test, and no adjustments
ere made for multiple comparisons. Results were
nalyzed as of July 1, 2004.
ESULTS
ngraftment
Sustained engraftment was achieved in 41 of the
3 patients. Neutrophil counts of 0.5  109/L were
eached at a median of 19 days (range, 10-31 days).
wo patients died without meeting hematologic cri-
eria for engraftment, although 1 of these had clinical
nd histologic evidence of acute GVHD.
elapse
Recurrence (or progression) of CMML occurred
n 10 patients at 45 to 657 days (median, 150 days)
fter transplantation. The estimated probability of re-
apse at 4 years was 23%. There were no statistically
igniﬁcant correlations between the hazard of relapse
nd IPSS score, WHO classiﬁcation, age, use of high-
ose TBI, or disease duration before transplantation
Table 3). Patients with proliferative disease had a
lightly lower hazard of relapse, but outcome was not
tatistically signiﬁcantly different from that in patients
ith nonproliferative disease. There was a suggestion
hat the hazard of relapse was higher with a higher-
isk classiﬁcation by MDAPS (hazard ratio [HR], 3.79;
5% conﬁdence interval [CI], 0.80-17.92; P  .09).
o correlation of comorbidity index with relapse was
bserved (Table 3).
Six (33%) of 18 patients without chronic GVHD
elapsed, compared with 4 (19%) of 21 with chronic
VHD. With the numbers of observations available,
here was no signiﬁcant correlation between GVHD
nd relapse. 
16auses of Death
Causes of death are summarized in Table 4. Ten
atients died with relapse of CMML. Fifteen patients
34%) died from complications related to the trans-
lantation (nonrelapse mortality), including 8 patients
ith infections with or without concurrent GVHD
nd 5 patients with multiorgan failure.
verall and Relapse-Free Survival
With a follow-up of 230 to 5135 days (median,
096 days), 18 patients are alive in remission for an
stimated overall (and relapse-free) survival at 4 years
f 41% (Figure 1). All patients who relapsed died, and
he time from relapse to death was less than 100 days
or 6 of the 10 patients. As a result, regression models
or overall and relapse-free survival are similar, and we
resent those for overall survival only. Six of the 18
atients who received transplants from HLA-identical
iblings, 3 of 3 who received transplants from HLA-
onidentical relatives, 8 of 17 who received trans-
lants from HLA-identical unrelated donors, and 1 of
who received transplants from HLA-nonidentical
nrelated donors are alive. Patients with grade II to IV
cute GVHD had a higher hazard of mortality than
id patients with grade 0 or I acute GVHD; however,
he difference was not statistically signiﬁcant (HR,
.34; 95% CI, 0.61-2.98; P  .47). Survival was also
omparable for patients with and without chronic
VHD (HR, 1.06; 95% CI, 0.38-2.95; P .92). With
he number of patients available, no signiﬁcant effect
f conditioning regimen on outcome was observed. In
articular, there was no signiﬁcant difference between
atients conditioned with high-dose TBI and those
repared with chemotherapy-only regimens (Table 3).
here were no statistically signiﬁcant associations be-
ween overall survival and IPSS, WHO, or MDAPS,
or with classiﬁcation as proliferative versus nonpro-
iferative or with disease duration before transplanta-
ion. Increasing age was suggestively associated with
n increased hazard of death (Table 3).
Sorror et al. [13] showed in a previous study that
breakdown by scores into 0, 1 to 2, and 3 was
seful to evaluate risks of nonrelapse mortality and
verall survival. Here, patients were categorized
nto 2 groups only, by scores of 0 to 2 and 3,
ecause of the small cohort size. Patients with co-
orbidity scores of 3 had an increased hazard of
ortality compared with those who had lower
cores (HR, 2.81; 95% CI, 1.25-6.34; P  .01). The
orresponding probabilities of surviving in remis-
ion were 15% and 54% for patients with comor-
idity scores 0 to 2 and 3, respectively (Figure 2).
he comorbidities present in patients with scores of
3 are summarized in Table 5.
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Allogeneic Transplants for CMML
BISCUSSION
CMML is a hematopoietic stem cell disorder with
eterogeneous clinical presentation. The classiﬁcation
emains a matter of debate. The WHO classiﬁed
MML in a new category of MDS/myeloproliferative
isease [1]. Previously, the total WBC had been con-
idered to distinguish between truly dysplastic (MDS-
MML; WBC 13  109/L) and proliferative (my-
loproliferative disease-CMML; WBC 13  109/L)
ypes [9]. However, although the distinction of pro-
iferative and nonproliferative subtypes has provided
elevant survival information in some series, the prog-
ostic signiﬁcance of this classiﬁcation has been ques-
ioned [27-29]. A prognostic scoring system proposed
y the M.D. Anderson team categorizes patients on
he basis of clinical features into low-risk, intermedi-
te 1 or 2, and high-risk groups with median life
xpectancies ranging from 5 to 24 months. This em-
hasizes that despite the chronic nature implied by the
erm, CMML is often a rapidly progressive disease
nd that effective therapeutic strategies are needed.
HCT offers potentially curative therapy for pa-
ients with CMML; however, the risk of fatal compli-
ations is high, and the relevance of the various clas-
iﬁcation schemes to posttransplantation outcomes is
ot clear. Here, we present an update of results in
atients with CMML who underwent transplantation
able 3. Hazard Rates for Relapse, Nonrelapse Mortality, and Mortali
Characteristic/Score Relapse
PSS
0-1 1
1.5-3.5 1.72 (0.38-7.70; P  .48)
HO
CMML-1 1
CMML-2 1.59 (0.45-5.64; P  .47)
.D. Anderson
0-1 1
2-4 3.79 (0.80-17.92; P  .09)
CT-SCI
0-2 1
3-6 0.93 (0.19-4.49; P  .92)
onproliferative
CMML 1
roliferative CMML 0.66 (0.17-2.54; P  .54)
isease duration
<12 mo 1
>12 mo 0.89 (0.23-3.46; P  .87)
ge* 1.23 (0.75-2.02; P  .42)
onditioning regimen†
No TBI 1
High-dose TBI 1.12 (0.29-4.34; P  .87)
PSS indicates International Prognostic Scoring System; WHO, W
speciﬁc comorbidity index.
hown for the 3 end points are the reference value (1) and the rela
value).
Age was modeled as a continuous linear variable; hazard ratio repre
Excludes the patients who received nonmyeloablative transplants.t the FHCRC. We analyzed posttransplantation out- t
B&MTomes depending on pretransplantation classiﬁcation
nd risk assessments. Overall, the data conﬁrm the
esults reported previously in a smaller cohort of pa-
ients [6], with estimated overall and relapse-free sur-
ival at 4 years of 41%. These results compare favor-
bly to those of Kroger et al. [7], who observed a
elapse-free survival of 18% at 40 months. However,
hat study included patients from multiple institu-
ions, some of whom had received T cell–depleted
ransplants; this might have contributed to a higher
elapse rate than that reported here. This observation
ould suggest a graft-versus-leukemia effect in pa-
ients with CMML, even though in this study the
elapse incidence in patients with and without GVHD
id not differ signiﬁcantly.
In disagreement with our previous report [6], but
n agreement with reports by others [7,8], disease
uration by itself had no statistically signiﬁcant effect
n outcome. Furthermore, indicators of prognostic
igniﬁcance for the natural disease course, such as
HO classiﬁcation and IPSS scores, failed to con-
incingly deﬁne groups of patients with superior or
nferior outcome after transplantation. We were also
nable to demonstrate differences in outcome be-
ween proliferative and nonproliferative forms of the
isease, in agreement with previous data [2,29], al-
hough small patient numbers limited the power of
rious Characteristics and Scoring Systems
Nonrelapse Mortality Mortality
1 1
0.38 (0.08-1.85; P  .23) 0.74 (0.27-2.03; P  .55)
1 1
0.38 (0.09-1.68; P  .2) 0.77 (0.31-1.94; P  .58)
1 1
0.98 (0.36-2.73; P  .98) 1.51 (0.67-3.42; P  .32)
1 1
4.36 (1.59-12.34; P  .006) 2.81 (1.25-6.34; P  .01)
1 1
1.0 (0.35-2.8; P  .99) 0.82 (0.36-1.85; P  .63)
1 1
1.86 (0.67-5.13; P  .23) 1.45 (0.65-3.23; P  .36)
1.49 (0.91-2.43; P  .11) 1.38 (0.97-1.97; P  .08)
1 1
0.79 (0.28-2.23; P  .66) 0.87 (0.38-1.97; P  .74)
alth Organization; HCT-SCI, hematopoietic cell transplantation–
zard rate for the comparison value (with conﬁdence interval and P
he increase in hazard associated with an increase in age of 10 years.ty by Va
orld He
tive ha
sents the analysis. It is of note that in the patient cohort that
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7ormed the basis for the recently proposed MDAPS,
here was a trend for shorter survival among patients
ith leukocytosis (indicative of proliferative features),
ut no differences were observed in regard to the risk
f evolution into acute leukemia. In this analysis, the
DAPS score was not statistically signiﬁcantly asso-
iated with outcome, although results were suggestive
or relapse and overall survival. Because several con-
itioning regimens were used in our study, results
eed to be interpreted with caution. Nevertheless, if
onﬁrmed, the results would suggest that HCT
hould be offered to CMML patients earlier (lower-
isk categorization) rather than later in the disease
ourse. HCT seems to offer outcomes that are better
han what is achievable with nontransplantation ther-
py; when compared with the data that formed the
asis for the MDAPS proposal, the life expectancies
ith HCT were superior in all patients with CMML,
xcept possibly for those in the lowest MDAPS group,
ho had a median survival of 24 months.
Comorbid conditions, which are more frequent in
lder patients, are not reﬂected in any of the currently
sed classiﬁcation schemes for myelodysplastic and
yeloproliferative disorders. However, they seem to
ave a signiﬁcant negative effect on posttransplanta-
ion outcomes in patients with CMML, as previously
igure 1. Relapse-free survival. Eighteen patients are alive without
elapse; 5 of the 18 have been followed up for 9.6 to 14.1 years after
ransplantation and are indicated as censored at 9 years (censored
able 4. Causes of Death
Cause of Death
No. Patients
(%)
elapse 10 (23)
raft failure 1 (2)
ultiorgan failure 5 (12)
neumonia/pulmonary hemorrhage  GVHD 5 (12)
iral infection  GVHD 3 (7)
ntracranial bleed 1 (2)
VHD indicates graft-versus-host disease.atients are indicated by tick marks). L
18bserved in other disease categories [30,31]. The
CT-SCI has shown higher sensitivity in capturing
omorbidities and has more predictive power for mor-
ality among patients given myeloablative HCT than
he original Charlson comorbidity index [12,13]. Pa-
ients with comorbidity scores of 3 had a very high
ate of mortality. The use of this HCT-speciﬁc index
ay thus be useful to identify patients who are at high
isk of posttransplantation mortality and may assist in
igure 2. Probability of survival according to the hematopoietic cell
ransplantation–speciﬁc comorbidity index (HCT-SCI). Patients
ith scores of 0 to 2 (solid lines) were compared with patients with
cores of 3 to 6 (dotted line; 1 patient could not be scored because
f incomplete data). Four patients with scores of 0 to 2 are alive at
.6 to 14.1 years, and 1 patient with a score of 3 to 6 is alive at 12.2
ears. These patients are indicated as censored at 9 years in the
gure.
able 5. Individual Organ Comorbidities among Patients with Scores
f 3 as Assessed by the Hematopoietic Cell Transplantation–Speciﬁc
omorbidity Index (HCT-SCI) [12,13]
Patient No. HCT-SCI Comorbidities
7014 3 Mild elevation of LFTs; moderate
impairment of PFTs
7179 3 Mild elevation of LFTs; moderate
impairment of PFTs
6479 3 Severe impairment of PFTs
10537 3 Severe impairment of PFTs
15886 3 Severe impairment of PFTs
20834 3 Rheumatologic disease; obesity
20948 3 Severe impairment of PFTs
23033 3 Severe impairment of PFTs
10087 4 Mild elevation of LFTs; severe
impairment of PFTs
13618 4 Severe impairment of PFTs;
infection
11082 5 Mild elevation of LFTs; severe
impairment of PFTs; infection
15248 6 Mild elevation of LFTs; severe
impairment of PFTs;
arrhythmia; low ejection
fraction
06025 6 Myocardial infarction; severe
impairment of PFTs; peptic
ulcerFTs indicates liver function tests; PFTs, pulmonary function tests.
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Bhe selection of high-risk patients for different trans-
lantation regimens. No conclusions in this respect
an be drawn from this study, because only 2 patients
ere conditioned with reduced-intensity (nonmyeloa-
lative) regimens. One of these patients died with
elapse, and 1 is surviving in remission.
In summary, despite remaining problems, alloge-
eic HCT is currently the only treatment option with
urative potential for CMML. It resulted in estimated
verall and relapse-free survival at 4 years of 41%
54% for patients without major comorbidities). The
se of additional clinical or laboratory data, such as the
DAPS and the HCT-SCI, should help in arriving at
ecisions about the optimal timing of HCT and the
election of appropriate conditioning regimens.
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